Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer's and Parkinson's disease

Alan King Lun Liu, Raymond Chuen-Chung Chang, Ronald K B Pearce, Steve M Gentleman, Alan King Lun Liu, Raymond Chuen-Chung Chang, Ronald K B Pearce, Steve M Gentleman

Abstract

It has been well established that neuronal loss within the cholinergic nucleus basalis of Meynert (nbM) correlates with cognitive decline in dementing disorders such as Alzheimer's disease (AD). Friedrich Lewy first observed his eponymous inclusion bodies in the nbM of postmortem brain tissue from patients with Parkinson's disease (PD) and cell loss in this area can be at least as extensive as that seen in AD. There has been confusion with regard to the terminology and exact localisation of the nbM within the human basal forebrain for decades due to the diffuse and broad structure of this "nucleus". Also, while topographical projections from the nbM have been mapped out in subhuman primates, no direct clinicopathological correlations between subregional nbM and cortical pathology and specific cognitive profile decline have been performed in human tissue. Here, we review the evolution of the term nbM and the importance of standardised nbM sampling for neuropathological studies. Extensive review of the literature suggests that there is a caudorostral pattern of neuronal loss within the nbM in AD brains. However, the findings in PD are less clear due to the limited number of studies performed. Given the differing neuropsychiatric and cognitive deficits in Lewy body-associated dementias (PD dementia and dementia with Lewy bodies) as compared to AD, we hypothesise that a different pattern of neuronal loss will be found in the nbM of Lewy body disease brains. Understanding the functional significance of the subregions of the nbM could prove important in elucidating the pathogenesis of dementia in PD.

Figures

Fig. 1
Fig. 1
A diagram of the human basal forebrain illustrating the location of the substantia innominata (as outlined). AC anterior commissure, Am amygdala, Cd caudate, GP globus pallidus, IC internal capsule, LV lateral ventricle, Pt putamen, SI substantia innominata
Fig. 2
Fig. 2
Projected innervation map of the various Ch4 regions (Ch4a, green; Ch4i, blue; Ch4p, red) in the human brain on the lateral surface (top left) and at the mid-sagittal plane (top right). Cortical projection from the Ch4ai (turquoise) is currently unknown in the human brain. Topographical innervation in different subsectors of the nbM according to Mesulam et al. (bottom) [67, 69]
Fig. 3
Fig. 3
Formalin-fixed, paraffin-embedded basal forebrain sections available from the Parkinson’s UK Tissue Bank at Imperial College, London, stained with H&E (ac; gi) and serial sections stained with choline acetyltransferase (ChAT) immunohistochemistry (Millipore AB144P, 1:100 with pressure cooker pretreatment in pH 6.0 citrate buffer) (df; jl). Six subdivisions of the basal forebrain were defined and arranged rostrally (top left) to caudally (bottom right). a, d Level at nucleus accumbens. This level is defined by the absence of anterior commissure and the presence of a large caudate head with nucleus accumbens. b, e Pre-anterior nbM level. Anterior commissure appears in this section but it is located ventral to the globus pallidus and is rostral to decussation level. A large ventral striatum could be seen clearly with ChAT immunohistochemistry. c, f Most rostral anterior nbM level. This level is defined by the decussation of the anterior commissure. Ch4 neurons are defined by their location being lateral to the supraoptic nucleus and they are orientated at the medial–lateral axis parallel to the basal border of the section. g, j Most caudal anterior nbM level. The anterior commissure is split into two parts with medial end still decussating and lateral end located ventral to the globus pallidus. h, k Intermediate nbM level. At this level, the globus pallidus is split into the external and internal components by an inter-medullary lamina. The anterior commissure is located ventral to the putamen and sometimes the infundibulum could be seen. i, l Posterior nbM level. This is defined by the presence of mammillary body, small or absence of caudate and internal capsule occupying the medial half of the tissue. Asterisk denotes area of maximal density of ChAT-immunopositive cells in the nbM. Zoomed-in figure showing the ChAT-immunopositive neurons in the nbM at ×10 objectives. AC anterior commissure, Cd caudate, fx fornix, GP globus pallidus, GPe globus pallidus externa, GPi globus pallidus interna, ic internal capsule, inf infundibulum, mb mammillary body, nAcc nucleus accumbens, ot optic tract, Pt putamen, son supraoptic nucleus, VS ventral stratum
Fig. 4
Fig. 4
Photographs showing the anatomical landmarks for the anterior, intermediate and posterior levels of the nucleus basalis of Meynert (nbM, as indicated by asterisk). At dissection, the first coronal slice is made through the mammillary body (MB), revealing the posterior nbM. Using a 0.5-cm cutting guide two further coronal slices will reveal the intermediate and anterior levels. These are specifically identified by the presence of discernible globus pallidus externa (GPe) and interna (GPi), and midline anterior commissure (AC), respectively. With normal anatomical variation between individuals, this general 0.5 cm interval may need slight modification, depending on brain size
Fig. 5
Fig. 5
Projected schema of anatomical progression of pathology within the nbM with possible clinicopathological correlations. Hypothesised progression is indicated by dashed arrows

References

    1. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:164–171.
    1. Allen SJ, Dawbarn D, Wilcock GK. Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer’s disease. Brain Res. 1988;454:275–281.
    1. Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010;9:1128–1138.
    1. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s Disease. Acta Neuropathol. 1983;61:101–108.
    1. Arendt T, Bigl V, Tennstedt A, Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer’s disease. Neuroscience. 1985;14:1–14.
    1. Arendt T, Schindler C, Brückner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein epsilon 4 allele. J Neurosci. 1997;17:516–529.
    1. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology. 1992;42:1681–1688.
    1. Ayala G. A hitherto undifferentiated nucleus in the forebrain (nucleus subputaminalis) Brain. 1915;37:433–448.
    1. Bartus RT, Dean RL, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–414.
    1. Boban M, Kostovic I, Simic G (2006) Nucleus subputaminalis: neglected part of the basal nucleus of Meynert. Brain 129:E42; author reply E43. doi:10.1093/brain/awl025
    1. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253:242–247.
    1. Bohnen NI, Müller MLTM, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–1676.
    1. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60:1745–1748.
    1. Bohnen NI, Müller MLTM, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133:1747–1754.
    1. Brockhaus H. Vergleichend-anatomische Untersuchungen über den Basalkernkomplex. J Psychol Neurol. 1942;51:57–95.
    1. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11:301–307.
    1. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci. 1983;59:277–289.
    1. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down’s syndrome. Ann Neurol. 1985;18:310–313.
    1. Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol. 1988;273:543–557.
    1. Chui HC, Mortimer JA, Slager U, et al. Pathologic correlates of dementia in Parkinson’s disease. Arch Neurol. 1986;43:991–995.
    1. Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain. 2011;134:1493–1505.
    1. Cullen KM, Halliday GM. Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiol Aging. 1998;19:297–306.
    1. Darvesh S, Freedman M. Subcortical dementia: a neurobehavioral approach. Brain Cogn. 1996;31:230–249.
    1. Divac I. Magnocellular nuclei of the basal forebrain project to neocortex, brain stem, and olfactory bulb. Review of some functional correlates. Brain Res. 1975;93:385–398.
    1. Doucette R, Fisman M, Hachinski VC, Mersky H. Cell loss from the nucleus basalis of Meynert in Alzheimer’s disease. Can J Neurol Sci. 1986;13:435–440.
    1. Dunning CJR, Reyes JF, Steiner JA, Brundin P. Can Parkinson’s disease pathology be propagated from one neuron to another? Prog Neurobiol. 2012;97:205–219.
    1. Engelhardt E. Meynert and the basal nucleus. Dement Neuropsychol. 2013;7:435–438.
    1. Etienne P, Robitaille Y, Gauthier S, Nair NP. Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer’s disease. Can J Physiol Pharmacol. 1986;64:318–324.
    1. Etienne P, Robitaille Y, Wood P, et al. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer’s disease. Neuroscience. 1986;19:1279–1291.
    1. Föorstl H, Levy R. F. H. Lewy on Lewy bodies, parkinsonism and dementia. Int J Geriatr Psychiatry. 1991;6:757–766.
    1. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155–159.
    1. Fujishiro H, Umegaki H, Isojima D, et al. Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies. Acta Neuropathol. 2006;111:109–114.
    1. Garcia-Garcia D, Clavero P, Gasca Salas C, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2012;39:1767–1777.
    1. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol. 1984;64:43–52.
    1. González-Redondo R, García-García D, Clavero P, et al. Grey matter hypometabolism and atrophy in Parkinson’s disease with cognitive impairment: a two-step process. Brain. 2014;137:2356–2367.
    1. Gorry JD. Studies on the comparative anatomy of the Ganglion Basale of Meynert. Acta Anat (Basel) 1963;55:51–104.
    1. Gratwicke J, Kahan J, Zrinzo L, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37:2676–2688.
    1. Hall H, Reyes S, Landeck N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014
    1. Halliday GM, Song YJC, Harding AJ. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson’s disease. J Neural Transm. 2011;118:713–719.
    1. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391–403.
    1. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007;33:599–614.
    1. Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: the dual hit theory revisited. Ann NY Acad Sci. 2009;1170:615–622.
    1. Heimer L, De Olmos JS, Alheid GF, et al. The human basal forebrain. Part II. In: Floyd E, Bloom A, Bjorklund T, et al., editors. The primate nervous system, part 3. Amsterdam: Elsevier; 1999. pp. 57–226.
    1. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716–1722.
    1. Imamura T, Ishii K, Hirono N, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB) Neuroreport. 1999;10:1903–1907.
    1. Iraizoz I, Guijarro JL, Gonzalo LM, de Lacalle S. Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathol. 1999;98:186–196.
    1. Iraizoz I, de Lacalle S, Gonzalo LM. Cell loss and nuclear hypertrophy in topographical subdivisions of the nucleus basalis of Meynert in Alzheimer’s disease. Neuroscience. 1991;41:33–40.
    1. Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14:626–636.
    1. Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm. 2014
    1. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol. 2006;112:253–260.
    1. Kalaitzakis ME, Walls AJ, Pearce RKB, Gentleman SM. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiol Dis. 2011;41:377–384.
    1. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol. 2008;67:155–161.
    1. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.
    1. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9:1200–1213.
    1. Kievit J, Kuypers HG. Basal forebrain and hypothalamic connection to frontal and parietal cortex in the Rhesus monkey. Science. 1975;187:660–662.
    1. Kilimann I, Grothe M, Heinsen H, et al. Subregional basal forebrain atrophy in Alzheimer’s disease: a multicenter study. J Alzheimers Dis. 2014;40:687–700.
    1. Kim HJ, Lee JE, Shin SJ, et al. Analysis of the substantia innominata volume in patients with Parkinson’s disease with dementia, dementia with Lewy bodies, and Alzheimer’s disease. J Mov Disord. 2011;4:68–72.
    1. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–892.
    1. Koelliker A (1896) Handbuch der Gewebelehre des Menschen. In: Nervensystem des Menschen und der Thiere. vol 2, 6th edn. W. Engelmann, Leipzig
    1. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40:399–410.
    1. Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia. Mol Psychiatry. 2014
    1. Lehéricy S, Hirsch EC, Cervera-Piérot P, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease. J Comp Neurol. 1993;330:15–31.
    1. Lewy F. Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilk. 1913;50:50–55.
    1. Mann DM, Yates PO, Marcyniuk B. Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984;10:185–207.
    1. McGeer PL, McGeer EG, Suzuki J, et al. Aging, Alzheimer’s disease, and the cholinergic system of the basal forebrain. Neurology. 1984;34:741–745.
    1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872.
    1. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol. 1988;275:216–240.
    1. Mesulam MM, Van Hoesen GW. Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortex. Brain Res. 1976;109:152–157.
    1. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical coa, diagonal band nuclei, connections of the septal areleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214:170–197.
    1. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Neuroscience. 1984;12:669–686.
    1. Meynert T, Putnam J (translated) (1872) The brain of mammals. In: Stricker S (ed) A Man. Histol. W. Wood & company, New York, pp 650–766
    1. Mufson EJ, Cochran E, Benzing W, Kordower JH. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer’s disease and Down’s syndrome. Dementia. 1993;4:237–250.
    1. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol. 1989;105:221–232.
    1. Nagai T, McGeer PL, Peng JH, et al. Choline acetyltransferase immunohistochemistry in brains of Alzheimer’s disease patients and controls. Neurosci Lett. 1983;36:195–199.
    1. Nagai T, Pearson T, Peng F, et al. Immunohistochemical staining of the human forebrain with monoclonal antibody to human choline acetyltransferase. Brain Res. 1983;265:300–306.
    1. Nakano I, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol. 1984;15:415–418.
    1. Papez JW, Aronson LR. Thalamic nuclei of Pithecus (Macacus) Rhesus. Arch Neurol Psychiatry. 1934;32:1–26.
    1. Pearson RC, Sofroniew MV, Cuello AC, et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer’s type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res. 1983;289:375–379.
    1. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48:413–421.
    1. Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69–79.
    1. Perry RH, Candy JM, Perry EK, et al. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer’s disease. Neurosci Lett. 1982;33:311–315.
    1. Rafii MS, Baumann TL, Bakay RA, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement. 2014;10:571–581.
    1. Raghanti MA, Simic G, Watson S, et al. Comparative analysis of the nucleus basalis of Meynert among primates. Neuroscience. 2011;184:1–15.
    1. Reil JC. Archiv für die Physiologie. 1809;5:147–171.
    1. Rinne JO, Paljärvi L, Rinne UK. Neuronal size and density in the nucleus basalis of Meynert in Alzheimer’s disease. J Neurol Sci. 1987;79:67–76.
    1. Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol. 1985;17:163–170.
    1. Saper CB, Chelimsky TC. A cytoarchitectonic and histochemical study of nucleus basalis and associated cell groups in the normal human brain. Neuroscience. 1984;13:1023–1037.
    1. Schaltenbrand G, Bailey P (1959) Einführung in die Stereotakischen Operationen Mit Einem Atlas des Menschlichen Gehirns (Introduction to stereotaxis with an atlas of the human brain). vol. 1–3. Georg Thieme, Stuttgart
    1. Schiller F. Fritz Lewy and his bodies. J Hist Neurosci. 2000;9:148–151.
    1. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73:273–278.
    1. Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy. Ann Neurol. 1999;46:62–69 .
    1. Simić G, Mrzljak L, Fucić A, et al. Nucleus subputaminalis (Ayala): the still disregarded magnocellular component of the basal forebrain may be human specific and connected with the cortical speech area. Neuroscience. 1999;89:73–89.
    1. Stayte S, Vissel B. Advances in non-dopaminergic treatments for Parkinson’s disease. Front Neurosci. 2014;8:113.
    1. Tagliavini F, Pilleri G. Basal nucleus of Meynert. A neuropathological study in Alzheimer’s disease, simple senile dementia, Pick’s disease and Huntington’s chorea. J Neurol Sci. 1983;62:243–260.
    1. Tagliavini F, Pilleri G, Bouras C, Constantinidis J. The basal nucleus of Meynert in idiopathic Parkinson’s disease. Acta Neurol Scand. 1984;70:20–28.
    1. Uhl GR, McKinney M, Hedreen JC, et al. Dementia pugilistica: loss of basal forebrain cholinergic neurons and cholinergic cortical markers. Ann Neurol. 1982;12:99.
    1. Vogels OJM, Broere CA, Ter Laak HJ, et al. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer’s disease. Neurobiol Aging. 1990;11:3–13.
    1. Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983;13:243–248.
    1. Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–126.
    1. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237–1239.
    1. Wilcock GK, Esiri MM, Bowen DM, Hughes AO. The differential involvement of subcortical nuclei in senile dementia of Alzheimer’s type. J Neurol Neurosurg Psychiatry. 1988;51:842–849.
    1. Wilcock GK, Esiri MM, Bowen DM, Smith CC. The nucleus basalis in Alzheimer’s disease: cell counts and cortical biochemistry. Neuropathol Appl Neurobiol. 1983;9:175–179.
    1. Williams MR, Marsh R, Macdonald CD, et al. Neuropathological changes in the nucleus basalis in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2013;263:485–495.
    1. Zaborszky L, Hoemke L, Mohlberg H, et al. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage. 2008;42:1127–1141.
    1. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337–341.

Source: PubMed

3
Se inscrever